<table>
<thead>
<tr>
<th>Title</th>
<th>Evaluation of dynamic tumour tracking radiotherapy with real-time monitoring for lung tumours using a gimbal mounted linac.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Matsuo, Yukinori; Ueki, Nami; Takayama, Kenji; Nakamura, Mitsuhiro; Miyabe, Yuki; Ishihara, Yoshitomo; Mukumoto, Nobutaka; Yano, Shinsuke; Tanabe, Hiroaki; Kaneko, Shuji; Mizowaki, Takashi; Monzen, Hajime; Sawada, Akira; Kokubo, Masaki; Hiraoka, Masahiro</td>
</tr>
<tr>
<td>Citation</td>
<td>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2014), 112(3): 360-364</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2014-09</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/2433/192774">http://hdl.handle.net/2433/192774</a></td>
</tr>
<tr>
<td>Right</td>
<td>© 2014 Elsevier Ireland Ltd.; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。This is not the published version. Please cite only the published version.</td>
</tr>
<tr>
<td>Type</td>
<td>Journal Article</td>
</tr>
<tr>
<td>Textversion</td>
<td>author</td>
</tr>
</tbody>
</table>

京都大学学術情報リポジトリ
Kyoto University Research Information Repository
Title:

Evaluation of dynamic tumour tracking radiotherapy with real-time monitoring for lung tumours using a gimbal mounted linac

Authors:

Yukinori Matsuo, MD, PhD; Nami Ueki, MD, PhD; Kenji Takayama, MD; Mitsuhiro Nakamura, PhD; Yuki Miyabe, MS; Yoshitomo Ishihara, MS; Nobutaka Mukumoto, PhD; Shinsuke Yano, RTT; Hiroaki Tanabe, MS; Shuji Kaneko, BS; Takashi Mizowaki, MD, PhD; Hajime Monzen, PhD; Akira Sawada, PhD; Masaki Kokubo, MD, PhD; and Masahiro Hiraoka, MD, PhD.

Affiliations:

1. Department of Radiation Oncology and Image-applied Therapy, Kyoto University Graduate School of Medicine, Kyoto, Japan
2. Division of Radiation Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan
3. Clinical Radiology Service Division, Kyoto University Hospital, Kyoto, Japan
4. Mitsubishi Heavy Industries, Ltd., Tokyo, Japan
5. Faculty of Medical Science, Kyoto College of Medical Science, Nantan, Japan
6. Department of Radiation Oncology, Kobe City Medical Center General Hospital, Kobe, Japan

Corresponding author:

Yukinori Matsuo, MD, PhD.

Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

Phone: +81-75-751-3762, fax: +81-75-771-9749

E-mail: ymatsuo@kuhp.kyoto-u.ac.jp

This paper consists of 21 pages and 2 tables. There are 2 supplementary figures.

Running head:

Dynamic tracking with real-time monitoring

Keywords: stereotactic body radiotherapy; lung cancer; dynamic tumour tracking; real-time monitoring; feasibility study
Abstract:

Purpose: To evaluate feasibility and acute toxicities after dynamic tumour tracking (DTT) irradiation with real-time monitoring for lung tumours using a gimbal mounted linac.

Materials and Methods: Spherical gold markers were placed around the tumour using a bronchoscope prior to treatment planning. Prescription dose at the isocentre was 56 Gy in 4 fractions for T2a lung cancer and metastatic tumour, and 48 Gy in 4 fractions for the others. Dose-volume metrics were compared between DTT and conventional static irradiation using in-house developed software.

Results: Of twenty patients enrolled, DTT radiotherapy was successfully performed for 16 patients, except 4 patients who coughed out the gold markers, one who showed spontaneous tumour regression, and one where the abdominal wall motion did not correlate with the tumour motion. Dose covering 95% volume of GTV was not different between the two techniques, while normal lung volume receiving 20 Gy or more was reduced by 20%. A mean treatment time per fraction was 36 minutes using DTT. With a median follow-up period of 13.2 months, no severe toxicity grade 3 or worse was observed.

Conclusions: DTT radiotherapy using a gimbal mounted linac was clinically feasible for lung treatment without any severe acute toxicity.
Introduction

Lung cancer is the leading cause of cancer-related deaths in most countries, including the US[1] and Japan[2]. There have been two trends in lung cancer in recent years. The first is the shift in the patient population to older ages[1,2], and the second is the gradual increase in the ratio of early stage lung cancer[3,4]. Thus, development of a new treatment modality that is appropriate for elderly patients with early stage lung cancer is desirable.

Stereotactic body radiotherapy (SBRT) was developed as a new treatment modality for early stage lung cancer in the late 1990s. Many retrospective studies and several multi-institutional prospective trials have demonstrated that excellent local control is obtained by SBRT, with acceptable toxicity[5–7]. Thus, SBRT is now an important treatment option for patients with early stage non-small-cell lung cancer who are medically inoperable and those who are elderly and relatively unfit for surgery.

The next innovation expected for lung SBRT is four-dimensional (4D) radiotherapy, which can cope with tumour movement. The lung expands periodically according to respiration and a lung tumour moves mainly in the craniocaudal direction. The amplitude of craniocaudal tumour motion is around 1 cm in mean, but can be 3-4 cm in some patients[8]. When the whole trajectory of a moving tumour is included in the irradiation field, larger volumes of healthy tissues are irradiated. The latter leads to a risk of toxicity[9–11], and accordingly, that might limit the indication of SBRT to smaller tumours. A new 4D...
irradiation technique that permits delivery of a dose to the tumour and limiting that to normal tissues by coping with respiratory motion, may have the potential to improve the outcomes and to expand the indications of SBRT.

The Vero4DRT (formerly called the MHI-TM2000; Mitsubishi Heavy Industries Ltd., Tokyo, Japan, and BrainLab AG, Feldkirchen, Germany)[12] has two special features that allow dynamic tumour tracking (DTT) with real-time monitoring. One is two sets of kilovoltage (kV) x-ray imagers, that can monitor the three-dimensional position of the tumour in real-time via implanted fiducial markers, and the other is a gimbal mounted linac, enabling DTT. Extensive evaluation of the characteristics of this DTT system demonstrated high accuracies in treatment delivery to a moving target[13–17]. Previous experimental validation offered the required confidence for clinical implementation of DTT treatment of lung tumours.

The purpose of this study was to evaluate feasibility and acute toxicities after DTT radiotherapy with real-time monitoring in SBRT for lung cancers using the Vero4DRT system.

Materials and Methods

Patients

Eligibility criteria were as follows: (1) a single lung tumour with a diameter of 50 mm or less, (2) no nodal or distant metastasis, (3) respiratory tumour movement of 5 mm or more, (4) age of 20 years or
above, (5) performance status of 0-2, (6) arms could be held over the head for 30 min or more, (7) doses to adjacent organs not exceeding the pre-determined constraints, which were the same as in the Japan Clinical Oncology Group protocol 0403[18], and (8) written informed consent. This study was approved by the institutional review board. It was registered with the UMIN Clinical Trials Registry in Japan (UMIN000005324).

Pre-planning procedures

Prior to treatment planning, spherical gold markers with a diameter of 1.5 mm (FMR-201CR; Olympus Medical Systems, Tokyo, Japan) were placed around the tumour under bronchoscopic guidance as an internal surrogate for the tumour position. Treatment planning was carried out 1 week after insertion of the gold markers. At least 3 markers were required for the DTT irradiation to be performed.

On the simulation day, the patient was fixed in a supine position with both arms raised using an individualized vacuum pillow (BodyFIX; Elekta AB, Stockholm, Sweden, or ESFORM; Engineering System, Matsumoto, Japan). Ten respiratory phases of 4D CT were acquired in axial cine mode using a 16-slice CT scanner (LightSpeed RT16 or BrightSpeed Elite; GE Healthcare, Little Chalfont, UK) and a real-time positioning management system (Varian Medical Systems, Palo Alto, US). Immediately after the 4D CT scan, a breath-hold CT scan was also acquired at the end of exhalation. The breath-hold CT
was sent to iPlan RT image (ver. 4.1; BrainLab AG) as a reference image. The coordinate for each phase image from the 4D CT was modified so that its centroid of the fiducial markers was matched with that in the breath-hold CT. Then, the 10 phase images were fused onto the breath-hold CT. After the CT scan, the patient was moved to the Vero4DRT to perform a 4D modelling[14], which correlates the external abdominal motion and the internal fiducial motion. The purpose of the modelling was to estimate the 4D modelling error and the peak-to-peak amplitude of tumour motion.

Treatment planning

Gross tumour volumes (GTVs) were delineated on the breath-hold CT and 10 phase images. An internal target volume for tracking (ITV) was defined as a composite of the eleven GTVs from the breath-hold CT and the 10 phase images (Supplementary Fig. 1). Because the phase images were registered based on the marker centroid, the ITV was supposed to compensate for tumour deformation and uncertainty in the positional relationship between the tumour and fiducial makers during respiration[19]. Planning target volume (PTV) for tracking was defined as the ITV plus setup error and additional margins to compensate the 4D modeling error, baseline drift of the abdominal position, and mechanical errors of the system. The setup error was estimated to be 2.5 mm in each direction as an inter-fraction positional variation between the fiducials and the tumour[19]. A margin for the 4D modelling error was defined as
a mean plus 2 times of standard deviation in the 4D model on the simulation day. A margin for the 
baseline drift was estimated as 10% of the tumour motion amplitude. The mechanical errors were 
defined as 0.5 mm[12]. The PTV margin was defined as a linear sum of these errors. At least 5 mm was 
required for the margin.

Monitor units (MUs) for the treatment beams were calculated using the X-ray voxel Monte Carlo 
algorithm in iPlan RT dose (ver. 4.5.1; BrainLab AG) on the breath-hold exhale CT. The prescription 
dose was 48 Gy in four fractions for stage IA lung cancer, and 56 Gy in four fractions for stage IB lung 
cancer and metastatic lung tumour. This dose was prescribed at the isocentre. We typically arranged 
seven beams: four non-coplanar and three coplanar beams. 6-MV x-ray beams were collimated to the 
PTV plus 5-mm margin with a multi-leaf collimator. A static SBRT plan with non-tracking beams, based 
on the motion-encompassing method[8], was also prepared as a backup if DTT irradiation could not be 
achieved for some reason. Dose distributions were evaluated with an in-house developed software that 
allows 4D dose calculation considering with the gimbal mounted linac[20]. The calculated dose 
distributions for the 10 phase CT images were accumulated into the exhale breath-hold CT with 
deformable image registration using MIM Maestro (ver. 5.2; MIM Software Inc., Cleveland, OH). If the 
dose-volume metrics in the tracking plan were diagnosed to be superior to those in the static plan, the 
patient underwent DTT irradiation.
**Irradiation of treatment beams**

First, the patient was laid on the pre-formed vacuum pillow. Set-up error was corrected for bony structures using the ExacTrac X-ray system. Second, a 4D model was built to correlate the infra-red markers on the abdomen with the internal fiducial markers. Then, irradiation could start in dynamic tracking mode with the beam following a location predicted by the 4D model based on the infra-red markers placed on the patient’s abdominal wall. During irradiation, the tumour and the internal fiducials were monitored visually every second with EPID and the kV imagers. If the fiducial markers displaced from the predicted positions by 3 mm or more in 3 consecutive frames on the kV images, the irradiation was interrupted and rebuilding the 4D model was considered.

**Follow-up after treatment**

Follow-up visits were planned at 2, 4, 6, 9, and 12 months within the initial year after SBRT and every 3 months thereafter. A CT scan was performed at each visit. The follow-up period was defined as the duration between the first day of treatment and the last follow-up visit or the date of death. Acute toxicity was defined as any treatment-related toxicities during the initial 6 months after the treatment. Toxicity grading was according to the Common Terminology Criteria for Adverse Events v.4.0.
Results

Twenty-two patients were enrolled into this study between August 2011 and July 2013. No patients experienced toxicities related to the insertion of fiducial markers. Twenty-two of the 101 inserted markers were coughed out before the CT simulation. Consequently, the number of remaining makers in 4 patients decreased to two, which is insufficient for DTT to be performed. The planning procedures for DTT could not be performed in another two patients. One patient showed thoracic breathing that prevented the Vero system from tracking a tumour based on the abdominal motion (Supplementary Fig. 2). In the other patient with histology-unproven primary lung cancer, the tumour spontaneously regressed during 10 days between the fiducial insertion and the simulation. For the remaining 16 patients, the CT simulation for DTT was successfully performed. Characteristics of the 16 patients are shown in Table 1.

The mean PTV volume reduced from 56.2 cm$^3$ to 39.6 cm$^3$ for the static and tracking plans, respectively (Table 2). GTV doses were not spoiled by the tracking method (dose covering 95% volume of GTV, 93.4% vs. 93.7% of the prescription dose; $p = 0.323$ by paired $t$-test). Doses to the normal lung and liver were reduced in the 16 patients. Lung V20, the relative volume receiving 20 Gy or more, was reduced by 19.5%, from 5.5% to 4.4%. The tracking plan showed a higher maximal dose to the spinal cord than the
static plan in 5 patients. However, the difference did not exceed 0.3 Gy and was considered to be clinically acceptable.

The DTT irradiation was completed for all 64 fractions for the 16 patients. Mean and standard deviation in treatment time per fraction were 36.2 and 8.8 minutes (range, 19-70 minutes), respectively. The treatment time exceeded 50 minutes in 5 fractions because of communication failures between the tracking system and the gimbal system requiring a restart of the tracking procedure. The gold markers were well recognized with kV x-ray imagers throughout all treatment fractions. The 4D modelling was performed a mean of 1.9 times per fraction (range, 1 to 4).

With a median follow-up period of 13.2 months (range, 3.4–26.5 months), one patient experienced grade 2 radiation pneumonitis. No severe toxicity grade 3 or worse has been observed in any of the patients. Two patients died of cancer, and one died of infectious pneumonia. Local tumour control was achieved except one patient who developed local recurrence at 12.0 months.

**Discussion**

The Vero4DRT system has two major advantages. The first is that tumour position can be monitored in real time using kV imagers and an EPID. The second is that no extra treatment time over static SBRT and no special training for breath control are needed for the 4D treatment, which is clinically beneficial.
both for patient comfort and the throughput of the treatment system.

Several uncertainties are associated with 4D irradiation, including tumour position prediction errors and mechanical errors in beam delivery, which are problems to be overcome. In the Vero4DRT, kV imagers can ensure that the positions of the tumour and fiducial markers correspond to the predicted sites. EPID can be used to verify the tumour position in complement to the kV imagers[21]. Furthermore, log files allow retrospective confirmation of the accuracy in the delivery of tumour tracking after treatment. Our previous study, which evaluated the initial 10 patients from the present study cohort, confirmed high accuracies in the tracking performance. The 95th percentiles of overall tracking errors were 1.3 mm, 2.4 mm and 1.4 mm in left-right, cranio-caudal and anterior-posterior directions, respectively[22].

The Task Group 76 of the American Association of Physicists in Medicine classified motion management methods into five types: motion-encompassing, respiratory gating, breath-hold, forced shallow breathing with abdominal compression, and real-time tumour-tracking methods[8]. The motion-encompassing method is the most conventional and well-established. However, it uses the largest field of the five methods, with a large PTV. The breath-hold technique and abdominal compression are not always suitable for frail and elderly patients. Respiratory gating needs a longer treatment time than motion-encompassing methods. With a dynamic tracking method, patients do not need to hold or limit their breath, and the tumour is always irradiated by the treatment beams without intermittence, leading to
a shorter treatment time than the breath-hold methods or the gating methods, and a comparable treatment time to the motion-encompassing methods. Dynamic tumour tracking is considered to be the favourable method among the five motion management methods from the patient compliance and comfort points of view. According to a Japanese survey of SBRT in 2009[23], the most frequent response regarding the time needed for a single daily fraction was 30 min, followed by 40 min. Our result of 36.2 min for a single fraction was thus comparable with standard times for SBRT in Japan. In addition to patient comfort, a few studies have suggested that prolongation of the treatment time for a single fraction may reduce its biological effectiveness[24,25]. Unfortunately, considerable prolongation of treatment time over 50 minutes occurred in 5 fractions in the present study. The cause for the prolongation was immaturity of the tracking system including software. To realize DTT irradiation, the tracking software needed to communicate with other systems in real time and to command several operations including control of the gimbal motion, process of signals from the infra-red camera and analysis of images from the kV x-ray imagers. The tracking system had initial instability in the communication process where the system could not simultaneously execute such different tasks. Some adaptations to the tracking system have been introduced after the present study with the aim of improving stability. Volumetric modulated arc therapy, which can reduce total MUs and consequently reduce treatment time, is being applied to SBRT for the lung[26]. Arc irradiation application to DTT is needed for reduction of treatment time with
the Vero4DRT. The Vero4DRT achieved the same level of geometric and dosimetric accuracy with conformal arc DTT irradiation as that with fixed-port DTT[27]. A treatment planning system capable of VMAT plan is under development for the Vero4DRT.

The disadvantages of the current Vero4DRT system are its dependence on 4D modeling and fiducial marker insertion. If no appropriate 4D model is acquired, dynamic tracking cannot be performed, as occurred in one patient. One solution for this issue is to track a tumor based on real-time stereo fluoroscopy without any 4D model. However, this method introduces another problem of skin doses due to the continuous fluoroscopy during a treatment time. Another way to improve the 4D model is a training to encourage for patients to perform periodical abdominal breathing[28].

The Vero4DRT currently requires fiducial markers with x-ray fluoroscopy monitoring to detect the tumor position and create the 4D model. Two types of fiducials are applicable to the Vero4DRT: one is a spherical marker, and the other is a cylindrical marker. We used the spherical gold markers that were inserted into a peripheral bronchiole under bronchoscopy. This method was reported in more detail by Imura et al. from Hokkaido University[29]. All 57 patients in their report tolerated the marker implantation procedure and only one experienced pneumothorax, which resolved with bed rest. The toxicity rate was much lower than those of percutaneous insertion methods[30,31]. Trade-offs, however, for the reduced toxicity are marker dislocation between insertion and radiotherapy, and positional
uncertainty between the tumour and makers. Imura et al. reported that 25% of the inserted markers could not be detected throughout the treatment period. Indeed, 22% of the markers in this study were coughed out before the CT simulation, and 4 of 22 (18%) patients could not undergo the DTT due to the marker dislocation. The reason why the Vero4DRT system requires 3 markers or more in the use of spherical markers is to detect the marker dislocation. Regarding the positional uncertainty between the tumour and markers, Ueki et al. evaluated intra- and interfractional variations[19]. Root mean squares in the intrafractional variations were 0.6 mm, 0.9 mm and 1.5 mm in the right-left, anteroposterior and craniocaudal directions, respectively. Moderate correlations of the intrafractional variation with tumour motion amplitude and tumour-marker distance were observed with correlation coefficients of 0.549–0.780. However, the intrafractional error did not always distribute symmetrically around zero, but often distributed in one side above or below zero. The direction and amplitude of the intrafractional variations varied between patients. Base on the results, we judged that a uniform isotropic margin was inadequate to cover the intrafractional variations, and that the fused CT approach as in the Method section was suitable for DTT planning. The interfractional variation could be covered by a 2.5-mm margin.

In conclusion, DTT radiotherapy with real-time monitoring using a gimbal mounted linac was clinically feasible for the lung without any severe acute toxicity.
Conflict of interests:

T.M., M.K. and M.H. have consultancy agreements with Mitsubishi Heavy Industries Ltd., Japan. A sponsored research program is provided by Mitsubishi Heavy Industries Ltd.

Funding resources:

This research was funded by the Japan Society for the Promotion of Science (JSPS) through the “Funding Program for World-Leading Innovative R&D in Science and Technology (FIRST) Program,” initiated by the Council for Science and Technology Policy (CSTP).

The funding program had no effect on the study design or the interpretation of data.

References


**Figure legend:**

Supplementary figure 1. A schema for definition of an internal target volume (ITV) for tracking

a) An example of intrafractional change in alignment of gross tumour volume (GTV) and fiducial markers, and intrafractional tumour deformation.

b) Definition of ITV for tracking. The GTVs are fused based on the marker centroids. Then, an ITV for tracking (the thick red line) is defined as a composite of the fused GTVs.

c) A screenshot from a case. Several lines with various colours are shown around the tumour, which indicate GTVs from phase images of 4D CT. An ITV (not shown) is defined as a volume including all the GTVs. The outermost pink line indicates a planning target volume for the ITV.

Supplementary figure 2. A patient who showed thoracic breathing
The tumour position in the superior-inferior (SI) direction and the abdominal wall position in the anterior-posterior (AP) direction are shown in blue and red lines, respectively. Note that the patient showed thoracic breathing where the tumour moved without any abdominal motion during the initial 10 seconds. Thoracic breathing was the dominant respiratory pattern in the patient so that the Vero system could not create an appropriate 4D model for the patient.
exhale mid-inhale end-inhale
caudal
respiratory motion ➔ cranial

- fiducial markers
- centroid of markers
- GTV

a)
ITV for tracking